Pfizer faces renewed bid for Xalkori royalties as appeals panel revives NYU lawsuit
Fierce Pharma ------- Pfizer thought it had escaped the prospect of paying tens of millions in royalties on its lung cancer drug Xalkori. But an appeals court resurrected New York University's claims for a share of the drug's sales, ruling that a lower court erred in tossing NYU’s lawsuit against the drugmaker. In a 3-2 decision released Tuesday, the appeals judges said they couldn’t determine whether NYU is actually entitled to royalties on Xalkori (crizotinib), only that the earlier dismissal was invalid. Writing in the prevailing opinion, Justice Richard T. Andrias argued that “to the extent Pfizer, on its own, discovered that crizotinib could treat” a specific lung cancer, “the discovery of crizotinib was still derived in part through NYU's research technology.” To learn more click on the picture below to read the article.